NCT04497298View on ClinicalTrials.gov

Clinical Trial to Evaluate the Safety and Immunogenicity of the COVID-19 Vaccine

PHASE1CompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

August 10, 2020

Primary Completion Date

May 12, 2021

Study Completion Date

May 12, 2021

Conditions
COVID-19
Interventions
BIOLOGICAL

Two COVID-19 vaccine candidate (TMV-083/V-591) administrations - Low dose

Live-attenuated recombinant measles vaccine virus vector expressing a modified surface glycoprotein of the novel Coronavirus (SARS-CoV-2)

BIOLOGICAL

Two COVID-19 vaccine candidate (TMV-083/V-591) administrations - High dose

Live-attenuated recombinant measles vaccine virus vector expressing a modified surface glycoprotein of the novel Coronavirus (SARS-CoV-2)

BIOLOGICAL

One COVID-19 vaccine candidate (TMV-083/V-591) administration - High dose

Live-attenuated recombinant measles vaccine virus vector expressing a modified surface glycoprotein of the novel Coronavirus (SARS-CoV-2) and placebo

OTHER

Placebo

Physiological saline solution (0.9% NaCl)

Trial Locations (2)

2060

SGS Life Sciences, Clinical Pharmacology Unit, Antwerp

75014

CIC Cochin - Pasteur, Paris

Sponsors

Lead Sponsor

Institut Pasteur
All Listed Sponsors
collaborator

Themis Bioscience GmbH

INDUSTRY

collaborator

Coalition for Epidemic Preparedness Innovations

OTHER

lead

Institut Pasteur

INDUSTRY

NCT04497298 - Clinical Trial to Evaluate the Safety and Immunogenicity of the COVID-19 Vaccine | Biotech Hunter | Biotech Hunter